RCRC
15.10.2019 16:51:08 CEST | Business Wire | Press release
The Royal Commission for Riyadh City (RCRC), formally known as Riyadh Development Authority, has invited international experts to participate in a Symposium setting out the next chapter in Riyadh’s development as a sustainable city, one that will enhance the lives of its citizens, while finding solutions to the difficult challenges facing all cities across the world today.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191015005797/en/
‘Riyadh’s Sustainable Future’ Symposium will take place on November 12 & 13, 2019 in Riyadh and will focus on four of the capital’s most ambitious projects, launched by King Salman bin Abdulaziz Al Saud, and stemming from an initiative from Prince Mohammed bin Salman bin Abdulaziz Al Saud, the Crown Prince.
These four projects are transformative and will help to establish Riyadh as one of the most livable cities in the world.
King Salman Park (www.riyadhksp.sa/en/ ) promises to be the largest green city park in the world; Sports Boulevard (www.riyadhalmasar.sa/en/ ) will be a state-of-the-art new health and wellness destination in the heart of the city; Green Riyadh (www.riyadhgreen.sa/en/ ) will focus on planting 7.5 million trees all over the city; and Riyadh Art (www.riyadhart.sa/en/ ) will delight art lovers with its 1,000 curated art pieces, iconic installations and annual arts festival through its world-class interactive public arts program.
The Symposium will invite discussion across a variety of subject areas, including climate change; sustainable urban development; conservation of the natural environment; critical resource management; energy conservation, production and management; legal frameworks and initiatives to support positive change; and transformative social activation.
The four projects complement Saudi Vision 2030’s ‘Quality of Life’ Program and are aligned with the U.N. Sustainable Development Goals, to create sustainable cities and communities, while driving urgent action against climate change.
Professor David Griggs, an expert in sustainable city planning, who will be attending the Symposium, commented: “The challenge of transforming a rapidly growing city in the desert into a sustainable, responsible, and inspiring place to live is enormous. The world’s largest urban parks, 7.5 million trees to green the city, a 135 km sports corridor and more than 1,000 pieces of public art, are just four of the projects that will transform the city. The ‘Riyadh’s Sustainable Future’ Symposium will bring together some of the world’s leading experts to provide their wisdom and advice for these projects and, in doing so, help Riyadh towards a future its citizens and the world can be proud of.”
For Riyadh and its citizens, the ultimate goal is to create a more sustainable city and a thriving, active community in the long term, while acting against climate change concerns. This Symposium is an important step in achieving that goal.
*Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20191015005797/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
WHOOP Expands Commitment to Women's Health by Including One-Year Subscription of Natural Cycles° App in Membership4.8.2026 11:00:00 CEST | Press release
The integration gives eligible WHOOP members seamless access to the only FDA-cleared hormone-free birth control app, with the first year of Natural Cycles° included for those new to the app as part of their WHOOP membership. WHOOP, the human performance company, today announced an expansion of its women’s health offering through an integration with Natural Cycles° (NC°), the only FDA-cleared, hormone-free birth control app. WHOOP is offering a 12-month subscription to the NC° app to eligible new Natural Cycles users. Members with compatible WHOOP devices can now automatically share overnight skin temperature with the NC° app to enable personalized fertility insights and hormone-free birth control. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260804399367/en/ WHOOP Expands Commitment to Women's Health by Including One-Year Subscription of Natural Cycles° App in Membership The Natural Cycles app, a Class II medical device, u
Alphatax Makes Two Acquisitions to Strengthen Transfer Pricing Capabilities4.8.2026 10:00:00 CEST | Press release
Acquisitions Expand Transfer Pricing Offering and Support Long-Term Platform Strategy Alphatax, the global tax compliance software provider, has today announced the acquisitions of TP Accurate and Intra Pricing Solutions, expanding its transfer pricing capabilities and reinforcing its ambition to build the world's first tax operating system. The acquisitions strengthen Alphatax's transfer pricing portfolio with complementary capabilities across financial transactions and documentation. TP Accurate provides specialist software for intra-group financing arrangements, while Intra Pricing Solutions' flagship product, TPGenie, enables multinational organisations and advisors to produce transfer pricing documentation using intelligent automation and AI. Together, they expand Alphatax's ability to support the full transfer pricing lifecycle, helping customers manage compliance more efficiently while improving governance and reducing audit risk. They also represent another step towards Alphata
LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 09:10:00 CEST | Press release
LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The
“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 254.8.2026 09:00:00 CEST | Press release
Giant Hatsune Miku Returns to Light Up Tokyo’s Night! The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802298570/en/ © Crypton Future Media, INC. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@GICAL☆CURE! LOVE ♥ SHOT!” to life across the entire façade of the Tokyo Metropolitan Government Building. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.55 million. As one of Tokyo’s emerging landmark attractions, the
Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 09:00:00 CEST | Press release
Accomplished life sciences leader with a proven track record of driving successful development of novel therapeutics, joins Mosaic to guide its next phase of growthAllison brings three decades of drug development, board and executive leadership experience to support Mosaic’s transition towards a clinical-stage company Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 year
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom